Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Page 7 of 16
Jul 6, 2026Since its IPO, Veradermics has experienced exceptional gains, amassing market attention by aligning its hair loss research with the runaway success of the modern obesity drug market. CEO Reid Waldman’s acknowledgment of the consumer-driven 'weight loss craze' sheds light on shifting biotech priorities and the growing synergy between metabolic and dermatological health solutions.
Jul 5, 2026The latest funding round positions Celea Therapeutics to directly challenge established IPF therapies with its next-generation candidate. This pivotal trial could have far-reaching implications for patients struggling with progressive lung disease, the biotech landscape, and future standards of care in pulmonary medicine.
Jul 5, 2026Despite economic uncertainties, the biotech industry’s stock rally continues to outperform expectations as we move through 2026. The uptrend is reshaping investor optimism, R&D priorities, and the landscape for emerging and established biotech companies.
Jul 3, 2026For the first time, children under 12 with rare inherited blood disorders will have access to a gene therapy: Vertex’s Casgevy. The FDA’s recent approval under the agency’s National Priority Voucher program reflects both continued scientific progress and the careful approach regulators take to pediatric innovation.
Jul 3, 2026Roche is advancing its next-generation KRAS G12C inhibitor, divarasib, after Phase 3 data suggest it may offer greater potency and selectivity than current market options from Amgen and Bristol Myers Squibb. This announcement highlights an increasingly competitive race to address one of lung cancer’s most challenging genetic mutations and could mark a pivotal shift in standards of care for patients whose cancers are driven by KRAS G12C mutations.
Jul 3, 2026In a move poised to elevate standards in oncology, Color has introduced a new peer-to-peer component to its Expert Medical Opinion program, enabling oncologists to consult directly with top cancer specialists. This innovation could signal a transformation in how complex cancer diagnoses and treatments are validated and optimized, while amplifying the role of collaborative expertise in personalized care.
Jul 2, 2026The biopharmaceutical landscape continues to see vigorous acquisition activity in the rare disease space, with Ipsen initiating its second major buyout in a single week. This article explores the strategic importance and broader industry context of Ipsen’s $796 million agreement to acquire Memo Therapeutics and its promising monoclonal antibody program. The move reflects persistent enthusiasm for rare disease innovation and the ongoing drive for portfolio expansion through M&A.
Jul 1, 2026Dr. Cathleen Brown, medical director at Winona, discusses the launch of the Winona Research Initiative—a program dedicated to supporting and funding research that empowers women’s health, with a special emphasis on menopause. This effort could reshape future approaches, funding paradigms, and research agendas in an area that has long been under-resourced.
Jul 1, 2026In a landmark event for biotechnology and patient care, the FDA has greenlit Orca Bio’s T-cell therapy, offering hope for those confronting blood cancers and the complex complications of stem cell transplants. This approval not only underscores the progress of cell therapies but also highlights the challenges and opportunities ahead for the field.
Jun 30, 2026Ipsen has set the biopharma world abuzz with its $450 million deal to acquire Kartos Therapeutics, aiming to boost its oncology pipeline and deliver a unique, potentially transformative myelofibrosis therapy. The transaction revolves around navtemadlin, an oral small molecule targeting the tumor suppressor protein p53, and highlights the shifting strategic landscape in hematologic cancer drug development.
Jun 26, 2026Amid a dynamic landscape shaped by technological innovation and regulatory uncertainties, the annual BIO 2026 conference brought together industry leaders to discuss key trends, challenges, and the mood of the sector. This post examines the major takeaways as AI becomes an engine of both promise and debate in life sciences.
Jun 26, 2026The acquisition of Bio-Techne by Merck KGaA for $11 billion represents one of 2026’s most significant biopharma moves, positioning Merck squarely at the forefront of cell therapy innovation. This deal highlights a shifting landscape as companies seek to secure advanced manufacturing technologies and fortify their pipeline.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.